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Abstract Neuroactive steroids (NAS) allopregnanolone
(ALLO), Allotetrahydrodeoxycorticosterone (THDOC)
and dehydroepiandrosterone (DHEA) are important in the
regulation of mood and behavior. Knowledge about these
steroids in postmenopausal depression and the effect of
estrogen on NAS is lacking. We elected to determine if
there were differences in NAS between postmenopausal
depressed women and age matched controls. We also
investigated the effect of estradiol on NAS in post
menopausal depressed women receiving a selective seroto-
nin reuptake inhibitor (SSRI), and in non-depressed
postmenopausal controls. As part of a previously published
double blind study on estrogen acceleration of antidepres-
sant action, post menopausal women with major depression
receiving sertraline and healthy non depressed controls
were randomized to transdermal estrogen patch 0.1 mg or
placebo. NAS were measured at baseline and after 10 weeks
of treatment. Depressed subjects were treated with sertra-
line 50 mg/day to 100 mg/day for 9 weeks. At the baseline
and after treatment ALLO and DHEA were significantly
lower in depressed women compared to controls. Although
all depressed subjects experienced a positive clinical
response, estrogen administration was not associated with
changes in NAS in either the depressed or the asymptom-
atic postmenopausal women. The lower ALLO and DHEA
in postmenopausal depressed women suggests that symp-
toms of depression may be influenced by the synthesis or
fluctuation of these NAS. Estradiol exposure did not alter
ALLO, DHEA, or THDOC, implying these NAS are
unlikely to play a role in any mood changes in post





Steroids synthesized in the central nervous system can
influence neurophysiologic processes, mood, and behav-
ior. The term “neurosteroid” refers to endogenous steroids
synthesized from cholesterol in the central and peripheral
nervous system, independent of steroidogenic activity of
the endocrine glands (Baulieu 1991). The term “neuroac-
tive steroid” (NAS) subsequently was used to refer to
endogenous or exogenous steroids that have a direct
nongenomic effect on neuron excitability (Paul and Purdy
1992;L a m b e r te ta l .1995; Rupprecht 2003; Stoffel-
Wagner 2001; Pisu and Serra 2004). NASs bind to a
distinct site on the GABAA receptor and influence the
frequency and duration of the chloride channel openings,
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DOI 10.1007/s00737-009-0106-1thus modulating GABAergic transmission and GABA
mediated behaviors (Paul and Purdy 1992; Lambert et al.
1995; Majewska 1992;C o n c a se ta l .1999). Potent
neuroactive steroid modulators of the GABAA receptor
function include allopregnanolone (ALLO), allotetrahy-
drodeoxycorticosterone (THDOC), and dehydroepiandros-
terone (DHEA) (Rupprecht 2003; Majewska 1992).
THDOC and ALLO act as positive allosteric agonists of
the GABAA receptor while DHEA in the sulfated form can
display antagonistic properties at the GABAA receptor
(Majewska 1992).
Several authors have suggested that the disequilibrium of
NASs may be a factor in the pathogenesis of major
depression or a risk factor for the development of affective
symptoms (Rupprecht 2003; Pisu and Serra 2004; Bernardi
et al. 2004; Strous et al. 2006). In animal models of
depression, lower levels of allopregnanolone have been
found in the frontal cortex and amygdala (Uzunova et al.
2003). Exogenous administration of ALLO and DHEA in
preclinical and clinical models demonstrated antidepressant
effects (Uzunova et al. 2003; Khisti and Chopde 2000;
Khisti et al. 2000; Matsumoto et al. 1999; Pinna et al. 2003;
Serra et al. 2002; Wolkowitz et al. 1999). NAS have also
been implicated in the positive effect of selective serotonin
reuptake inhibitors (SSRIs). SSRIs were shown to catalyze
the rate limiting step in the synthesis of ALLO (Mellon and
Griffen 2002). In the olfactory bulbectomized rodent model
of depression, treatment with different antidepressant
medications that affect serotonin reversed the bulbectomy-
induced decline of ALLO (Uzunova et al. 2004; Uzunova
et al. 2006).
Menopause represents a time of vulnerability for onset of
depressive disorders (Rubinow et al. 1998; Joffe and Cohen
1998; Cohen et al. 2005); between 22 and 33% of
menopausal women report mood deterioration and depres-
sion (Zweifel and Obrien 1997). Significant changes in
hormonal concentrations occur at the time of menopause.
Estrogen concentrations decline precipitously and the
ensuing hypoestrogenic state has been linked with substan-
tial alterations in physical and psychological functioning.
Estrogen deficiency has been proposed to increase the
susceptibility for depression (Birkhauser 2002). In a large
meta-analysis, estrogen therapy appeared to be effective in
reducing symptoms of depression in menopausal women
(Zweifel and Obrien 1997). Exogenous estrogen has been a
useful monotherapy in treating depression during the
menopausal transition (Schmidt et al. 2000; Soares et al.
2001; Rasgon et al. 2002; Cohen et al. 2003), as well as an
augmentation strategy to antidepressant medication (West-
lund and Parry 2003; Liu et al. 2004; Morgan et al. 2005).
Studies in postmenopausal depression however, have not
been as consistent (Cohen et al. 2005; Morrison et al. 2004;
Rasgon et al. 2007).
Estrogen has been proposed to alleviate depression via
influencing serotonin and norepinepherine (Bethea et al.
2002). However, it has also been proposed that the
deterioration in mood in menopausal women may be related
to changes in levels of neuroactive steroids (Genazzani et al.
2005). Similar to estrogen, neuroactive steroids also decline
post menopausally (Bernardi et al. 2003; Barbaccia et al.
2000; Genazzani et al. 1998), and could conceivably
contribute to menopausal depression. Exposures to a variety
of menopausal hormone treatments have been shown to
increase ALLO and decrease DHEA in non-depressed
postmenopausal women (Bernardi et al. 2003; Pluchino et
al. 2005). NAS have not been evaluated in depressed
menopausal women given estrogen. Additionally, most
studies evaluating NAS and mood in reproductive-aged
women were not controlled or did not differentiate the effects
of estrogen from those of progesterone, the immediate
steroid precursor of the NAS (Bernardi et al. 2003; Pluchino
et al. 2005).
As part of a previously published study on estrogen
acceleration of SSRIs in postmenopausal depression (Rasgon
et al. 2007), we elected to determine if postmenopausal
women with and without major depression exhibit different
peripheral levels of the NAS ALLO, THDOC, DHEA, and
NAS precursor, PROG. We also investigated whether the
administration of a selective serotonin re-uptake inhibitor
(SSRI), sertraline with or without the addition of estrogen
influenced NAS concentration in postmenopausal women
with major depression. Finally, as prior reports of the
effect of hormone replacement with estrogen on NAS
were uncontrolled and often included progestins, we
assessed in a placebo controlled fashion, whether the
administration of estradiol to non-depressed menopausal
women affected NAS concentrations. We hypothesized
that NAS would be lower in the depressed women and that
both the administration of the E2 patch and the SSRI
would increase NAS concentrations.
Methods
Postmenopausal women with unipolar depression and
controls were recruited from the UCLA Mood Disorders
Program, newspaper advertisements, flyers, and other
community venues as previously described (Rasgon et al.
2007). Inclusion criteria required cessation of menses for a
minimum of 12 months, plasma levels of follicle stimulat-
ing hormone (FSH) greater than 40 mIU/ml and estradiol
(E2) levels less than 20 pg/ml. Subjects were required to
have a normal mammogram, pelvic examination, and
physical examination within 6 months of enrollment in
the study. Exclusion criteria included previous estrogen
replacement, prior antidepressant exposure, psychiatric
92 M.L. Morgan et al.disorders other than depressive disorder, current use of
hormonal medications, current use of tobacco, significant
vasomotor symptoms and medical illness in which estrogen
use may be contraindicated (cardiac disease, clotting
disorders, breast cancer, abnormal uterine bleeding, renal
disease, or liver disease). All subjects signed the informed
consent form approved by the UCLA Office for Protection
of Research Subjects prior to study enrollment. All
experimental procedures were conducted in accordance
with the Declaration of Helsinki. A Structured Clinical
Interview for DSM IV was administered to determine
whether subjects met inclusion criteria for major depressive
disorder (MDD), and to rule out other Axis I diagnoses.
Both depressed and control subjects were randomized to
estrogen or placebo transdermal patches from the onset of
the study in a double blind manner. Patches were applied
twice weekly to ensure maintenance of adequate estradiol
levels, with the estrogen patch release rate of .1 mg
estradiol/day. All depressed subjects received sertraline
concurrently with the estrogen or the placebo. The initial
dose of sertraline was 50 mg per day for the first week,
increased to 100 mg/day for the remainder of the study. The
Hamilton Rating Scale for Depression (Ham-D) was
conducted at the initial visit and weekly thereafter for ten
weeks. Individual items from the HAM-D for psychological
anxiety, somatic anxiety, and agitation were used to create
an anxiety scale. Baseline phlebotomy was conducted prior
to interventions and at the end of ten weeks of treatment to
measure serum ALLO, THDOC, DHEA, and PROG as part
of the larger study addressing differential treatment
response and cognition.
Steroid assay
Blood samples were collected in tubes containing clot-
activating factor and were immediately centrifuged. The
serum samples were stored at -80°C until assayed. For the
neurosteroid assay, 1 ml of serum was diluted with 2 ml of
water and then extracted three times with 3 ml of ethyl
acetate. The recovery (90%) of steroids through the
extraction procedure was monitored by adding a trace
amount of [
3H] cortisol (6,000– 8,000 cpm, 52 Ci/mmol).
The neurosteroids were quantified by radioimmunoassay as
previously described (Follesa et al. 2002) with specific
antibodies to DHEA and PROG (ICN, Milan, Italy,).
Antibodies to ALLO and THDOC were generated in
rabbits and sheep, respectively, and were provided by Dr.
R.H. Purdy (Scripps Research Institute, La Jolla, Calif.,
USA). The limit of detection of radioimmunoassay,
expressed as minimal amount of steroids distinguishable
from the zero sample was 0.01 ng. Intra- and inter-assay
coefficient of variations ranged between 5 and 7% and
between 9 and 11%, respectively. Estradiol was assayed by
commercial kit (ICN Pharmaceuticals, Costa Mesa, Calif.,
USA).
Data analysis
Independent t-tests were used to assess group differences in
demographic and baseline clinical variables. Between and
within group changes in NAS levels from baseline to end of
treatment were assessed with repeated measures analyses of
variance. Multivariate analysis of variance (MANOVA)
was used to analyze differences in NAS profiles between
depressed subjects and controls. MANOVA was also used
to assess group differences in NASs in depressed subjects
on sertraline plus estrogen versus sertraline plus placebo.
The relationship between mood and NAS concentrations
was evaluated with bivariate correlation analyses.
Results
Demographics Twenty eight postmenopausal subjects were
enrolled in the study. Sixteen met criteria for major
depressive disorder and 12 were asymptomatic controls.
Participants were randomized to receive either estrogen or
placebo with 8 depressed and 6 controls receiving estrogen,
and 8 depressed and 6 control subjects receiving placebo.
Means and standard deviations of age, years since meno-
pause, age at the time of menopause, parity, education,
body mass index (BMI), and baseline Ham-D are contained
in Table 1. No significant differences were seen between
depressed subjects and control subjects in the demographic
characteristics with the exception of education. Depressed
subjects had significantly less education than controls
(t=3.06, p<.05). BMI was higher in the depressed subjects
compared with controls however the difference did not
reach significance (p=.052). By definition, depressed
subjects had significantly higher Ham-D scores than control
subjects at baseline.
Baseline differences in NAS between depressed and normal
control subjects Table 2 contains descriptive statistics of
baseline concentrations of ALLO, THDOC, DHEA, and
PROG for depressed and control subject. Prior to treatment,
MANOVA revealed a significant omnibus test (F (4, 23)
)=
4.99, p=.005). Univariate follow-up tests indicated that
ALLO and DHEAwere significantly lower in the depressed
subjects compared to the healthy postmenopausal women
(t(26)=2.42, p=.023 and t(26)=2.48,p=.020 respectively).
Change in NASs from baseline to end of treatment Table 3
contains descriptive statistics for NAS before and after
estrogen or placebo treatment in depressed menopausal
women on SSRIs and healthy menopausal controls. There
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any of the NASs, nor were there significant interactions.
Effect of SSRI plus estrogen or placebo on NAS In depressed
subjects, NAS and PROG did not change significantly after
SSRI treatment plus estrogen or SSRI treatment plus
placebo.
As reported previously, all of the depressed women
responded to treatment with the sertraline (Rasgon et al.
2007). Estrogen did not alter the final response rate to
sertraline; however, the estrogen group improved more
rapidly than the placebo group (data not shown).
Discussion
To further understand the role of neuroactive steroids in
postmenopausal depression and mechanism of action of
estrogen and SSRIs in this disorder, we compared the
concentrations of serum ALLO, THDOC, DHEA and the
neuroactive precursor PROG between postmenopausal
women with depression and asymptomatic postmenopausal
controls. Neuroactive steroids were studied before and after
the administration of sertraline with the addition of estrogen
or placebo in the depressed group, and estrogen or placebo
(no SSRI) in the group of asymptomatic postmenopausal
women, as part of a larger double blind, placebo controlled
study of estrogen augmentation of SSRIs in post meno-
pausal women with depression (Rasgon et al. 2007). The
major finding of this current study was significantly lower
baseline DHEA and ALLO in postmenopausal women with
major depressive disorder compared with healthy controls.
In the depressed women, exposure to sertraline failed to
affect NAS concentrations. Estrogen administration did not
significantly alter NAS levels in either the depressed or
control subjects.
Our study supports previously published reports of lower
baseline levels of DHEA or DHEA in its sulfated form
(DHEAS) in depressed populations compared to controls
(Barbaccia et al 2000; Yaffe et al. 1998; Barrett-Connor et
al. 1999; Michael et al. 2000; Berr et al. 1996). However,
the literature on DHEA and depression is inconsistent with
publications also reporting higher levels (Tollefson et al.
1990; Osran et al. 1993; Heuser et al. 1998; Takebayashi et
al. 1998), or no differences (Fabian et al. 2001; Erdincler et
al. 2004; Romeo et al. 1998). The discrepancy in DHEA
results may be explained in part by differences in the age,
gender or health of the subjects (Van Broekhoven and
Verkes 2003). DHEA clearly declines with age and debility
(Orentreich et al. 1984) but our depressed subjects and
controls were comparable in age and were all healthy
except for the diagnosis of depression. Yaffe et al. (1998)
and Barrett-Connor et al. (1999) sampled large numbers
(n=699 and 394 respectively) of community dwelling
postmenopausal women, and both studies also found
DHEAs or DHEA to be non detectable or lower in
postmenopausal women with depressive symptoms com-
pared to postmenopausal controls. Barbaccia et al. (2000)
had similar findings in a sample of 25 postmenopausal
Depressed (n=16) Control (n=12) Total (n=28)
Mean SD Mean SD Mean SD
Age 54.50 4.99 57.91 5.59 55.89 5.42
Education (years)
a 14.91 1.54 17.18 2.32 15.83 2.18
Menopause (years) 5.33 4.40 9.06 6.68 6.73 5.54
Age at menopause 47.33 5.75 49.39 2.89 48.10 4.91
Parity 1.40 1.35 1.55 1.21 1.46 1.27
BMI 29.38 6.23 25.45 2.78 27.70 5.35
Baseline Ham-D
b 21.75 3.49 4.08 1.73 13.75 8.93
Table 1 Demographic variables
aDepressed subjects had signif-
icantly less education than con-
trols (t(25)=3.06, p<.05)
bDepressed subjects had signif-
icantly higher Ham-D scores
than controls (t(26)=17.28,
p<.001)
Table 2 Baseline neuroactive steroid concentrations (ng/ml) in depressed menopausal women and healthy menopausal controls
Depressed (mean ± sd) n=16 Controls (mean ± sd) n=12 t-statistic p-value
PROG 1.07±0.27 0.96±0 .20 -1.19 .243
ALLO 4.34±1.14 6.00±2.34 -2.42 .023
a
THDOC 1.69±0.87 4.73±6.86 1.76 .089
DHEA 0.81±0.49 1.57±1.09 2.48 .020
a
aStatistically significant difference (p<.05) between depressed subjects and controls in ALLO and DHEA at baseline
94 M.L. Morgan et al.depressed women. Morrison et al. (2001) found that lower
levels of DHEAs were correlated with higher depressive
scores in the older half of the sample (older than 41 years
versus younger than 41 years); by contrast, in the younger
half of the sample, higher DHEA levels correlated with
higher depressive scores. The hypothalamic-pituitary-
adrenal (HPA) axis stress response may differ in older
compared to younger depressed patients.
Lower plasma DHEA/S has also been associated with
higher levels of stress and with trait anxiety (Diamond et al.
1989). We did not find a correlation of NAS with anxiety in
our subjects. The role of DHEA in regulating mood remains
unknown. DHEAs are negative allosteric modulators of the
GABAA receptor (Majewska 1992) with paradoxical effects
in depression and anxiety as DHEA supplementation has
been reported to improve well being and depression in
elderly subjects and to be anxiolytic (Wolkowitz et al.
1999; Van Broekhoven and Verkes 2003; Morales et al.
1994; Yen et al. 1995; Wolkowitz et al. 1995).
The DHEA antidepressant action has been attributed,
among other theories, to augmentation of serotonin and
norepinepherine or to metabolism of DHEA to testosterone
or estrogen (Van Broekhoven and Verkes 2003; Morley et
al. 1997). As we previously reported, estrogen did
accelerate the antidepressant response compared with SSRI
treatment alone. We did not however see a change in
DHEA concentrations post treatment, which adds to the
inconsistent findings of effect of pharmacologic therapy on
DHEA levels (Van Broekhoven and Verkes 2003).
Our results also support previous reports of lower ALLO
in depressed subjects compared to controls (Romeo et al.
1998; Strohle et al. 1999; Uzunova et al. 1998). However,
not all studies have confirmed this relationship. ALLO was
found to be higher in depressed subjects than controls by
others (Barbaccia et al. 2000; Hardoy et al. 2006). ALLO
also produced antidepressive effects in the mouse forced
swim test model of depression (Khisti and Chopde 2000)
and has been postulated to act via the HPA axis and on
serotonin and norepinepherine neurotransmission (Van
Broekhoven and Verkes 2003). However these putative
antidepressant effects after the administration of ALLO
may not necessarily contribute to the efficacy of pharma-
cologic therapy. Contrary to the findings of others (Romeo
et al. 1998; Uzunova et al. 1998; Strohle et al. 2000), we
failed to find an increase in ALLO or THDOC after
treatment of depression with SSRIs, suggesting increases in
plasma ALLO are not required for treatment response.
Other studies utilizing partial sleep deprivation or repetitive
transcranial magnetic stimulation to treat depressed subjects
also found NAS were not affected by either intervention
regardless of response status (Schule et al. 2003; Padberg et
al. 2005). This study adds to the body of the literature
suggesting that a change in NAS is not essential for
successful treatment of depression (with or without phar-
macological interventions), or it is possible that the NAS
response may occur at later, not initial, stage of antidepres-
sant treatment.
Similarly, we did not find an increase in NAS after
estrogen supplementation. Others have found increased
ALLO and DHEA in non-depressed postmenopausal
women given various regimens of hormone therapy
(estrogen, estrogen/progestin, or tibolone), but the studies
were not controlled for placebo effect (Bernardi et al. 2003;
Pluchino et al. 2005). Additionally, our subjects lacked
menopausal symptoms and the increase in NAS found by
others could relate to improvement in menopausal symp-
toms. We also studied a small group of subjects and further
studies with larger numbers will be important.
There is considerably less literature on THDOC and
depression in clinical populations. Baseline THDOC levels
were found to be higher in depressed subjects compared to
controls (Strohle et al. 1999; Strohle et al. 2000). Similar to
others (Rupprecht and Holsboer 1999; Hardoy et al. 2006),
we detected no differences in THDOC in depressed
subjects compared to controls. However, the high standard
deviation may also account for failure of significance.
A consensus is forming from preclinical and clinical
research indicating that neuroactive steroids are involved
Depressed Control
Baseline End of treatment Baseline End of treatment
PROG Placebo 1.07±0.37 1.06±0.13 1.03±0.16 1.07±0.26
Estrogen 1.07±0.14 1.01±0.23 0.89±0.23 0.98±0.26
ALLO Placebo 4.18±1.17 3.99±0.44 7.39±2.84 6.10±1.66
Estrogen 4.51±1.16 4.30±0 .96 4.62±0.54 8.38±6.98
THDOC Placebo 1.64±1.00 1.84±0.90 8.19±8.58 8.98±10.11
Estrogen 1.75±0.79 2.00±0.96 1.28±1.12 1.23±1.01
DHEA Placebo 1.03±0.49 0.87±0.58 1.32±0.90 1.19±0.48
Estrogen 0.59±0.41 0.88±0.80 1.81±1.29 1.93±1.04
Table 3 Neuroactive steroid
concentrations (ng/ml) before
and after estrogen or placebo
treatment in depressed meno-
pausal women on SSRIs and
healthy menopausal controls
No significant changes in NAS
after estrogen or placebo treat-
ment in depressed or healthy
menopausal women
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response to treatment. However, a direct correlation with
NAS and diagnosis or outcome has not been definitively
established in humans. The specificity of the NAS assays
can also lead to discrepancies; gas chromatography, mass
spectrometry, or high performance liquid chromatography
and radioimmunoassays may give different levels of
NASs (Pearson Murphy and Allison 2000). Furthermore,
the results of this study are limited by the small sample
size and the fact that we were unable to compare the
effects of sertraline and estrogen on NAS in the early
versus late post menopausal state. Further research
including central nervous system NAS investigation is
also needed.
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